Glaxo Wellcome UK Ltd.
Glaxo Wellcome UK Ltd., a prominent player in the pharmaceutical industry, is headquartered in Great Britain. Established in 1995 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has since made significant strides in research and development, focusing on innovative medicines and vaccines.
With a strong presence in Europe, North America, and emerging markets, Glaxo Wellcome is renowned for its core products, including treatments for respiratory diseases, HIV, and vaccines. Their commitment to scientific excellence and patient-centric solutions sets them apart in a competitive landscape.
As a leader in the global healthcare sector, Glaxo Wellcome UK Ltd. has achieved notable milestones, including advancements in biopharmaceuticals and a robust pipeline of new therapies, solidifying its position as a trusted name in health and wellness.
+61 vs industry average
Glaxo Wellcome UK Ltd.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Glaxo Wellcome UK Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
No industry performance data available yet.
The Pharmaceutical Preparation Manufacturing industry
Reported emissions
No reported emissions data is available for Glaxo Wellcome UK Ltd. yet.
Glaxo Wellcome UK Ltd.'s reported carbon emissions
Glaxo Wellcome UK Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, which cascades its climate commitments and initiatives down to Glaxo Wellcome UK Ltd.
GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3). The company is also involved in various sustainability initiatives, such as the RE100, which aims for 100% renewable electricity, and the CDP, which focuses on transparency in environmental impact.
While specific reduction targets for Glaxo Wellcome UK Ltd. are not detailed, the overarching goals and strategies from GSK plc provide a framework for the subsidiary's climate commitments. As the company continues to align with these initiatives, it aims to contribute to a more sustainable future in the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Glaxo Wellcome UK Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Glaxo Wellcome UK Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from GSK plc
Carbon Disclosure Project
Inherited from GSK plcThe Climate Pledge
Inherited from GSK plcUN Global Compact Climate Champions initiative
Inherited from GSK plcRE 100
Inherited from GSK plcClimate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Glaxo Wellcome UK Ltd. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project